Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

478 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Serum tumor markers for the prediction of concordance between genomic profiles from liquid and tissue biopsy in patients with advanced lung adenocarcinoma.
Jiao XD, Ding LR, Zhang CT, Qin BD, Liu K, Jiang LP, Wang X, Lv LT, Ding H, Li DM, Yang H, Chen XQ, Zhu WY, Wu Y, Ling Y, He X, Liu J, Shao L, Wang HZ, Chen Y, Zheng JJ, Inui N, Zang YS. Jiao XD, et al. Among authors: inui n. Transl Lung Cancer Res. 2021 Jul;10(7):3236-3250. doi: 10.21037/tlcr-21-543. Transl Lung Cancer Res. 2021. PMID: 34430361 Free PMC article.
Biweekly combination therapy with gemcitabine and carboplatin compared with gemcitabine monotherapy in elderly patients with advanced non-small-cell lung cancer: a randomized, phase-II study.
Kusagaya H, Inui N, Karayama M, Nakamura Y, Kuroishi S, Yokomura K, Toyoshima M, Shirai T, Masuda M, Yamada T, Yasuda K, Suda T, Chida K. Kusagaya H, et al. Among authors: inui n. Lung Cancer. 2012 Sep;77(3):550-5. doi: 10.1016/j.lungcan.2012.05.106. Epub 2012 Jun 15. Lung Cancer. 2012. PMID: 22705118 Clinical Trial.
Clinicopathological and Survival Analysis of Japanese Patients with Resected Non-Small-Cell Lung Cancer Harboring NKX2-1, SETDB1, MET, HER2, SOX2, FGFR1, or PIK3CA Gene Amplification.
Inoue Y, Matsuura S, Kurabe N, Kahyo T, Mori H, Kawase A, Karayama M, Inui N, Funai K, Shinmura K, Suda T, Sugimura H. Inoue Y, et al. Among authors: inui n. J Thorac Oncol. 2015 Nov;10(11):1590-600. doi: 10.1097/JTO.0000000000000685. J Thorac Oncol. 2015. PMID: 26536195 Free article.
Heterogeneity analysis of PD-L1 expression and copy number status in EBUS-TBNA biopsy specimens of non-small cell lung cancer: Comparative assessment of primary and metastatic sites.
Yoshimura K, Inoue Y, Karayama M, Tsuchiya K, Mori K, Suzuki Y, Iwashita Y, Kahyo T, Kawase A, Tanahashi M, Ogawa H, Yokomura K, Inui N, Funai K, Shinmura K, Niwa H, Suda T, Sugimura H. Yoshimura K, et al. Among authors: inui n. Lung Cancer. 2019 Aug;134:202-209. doi: 10.1016/j.lungcan.2019.06.002. Epub 2019 Jun 5. Lung Cancer. 2019. PMID: 31319982
Prophylactic granulocyte-colony stimulating factor in patients with lung neuroendocrine carcinoma receiving platinum agents plus etoposide.
Watanabe H, Karayama M, Yasui H, Inoue Y, Hozumi H, Suzuki Y, Furuhashi K, Fujisawa T, Enomoto N, Nakamura Y, Inui N, Suda T. Watanabe H, et al. Among authors: inui n. Cancer Treat Res Commun. 2021;29:100493. doi: 10.1016/j.ctarc.2021.100493. Epub 2021 Nov 20. Cancer Treat Res Commun. 2021. PMID: 34844181 Free article.
Phase II study of erlotinib in elderly patients with non-small cell lung cancer harboring epidermal growth factor receptor mutations.
Inoue Y, Inui N, Asada K, Karayama M, Matsuda H, Yokomura K, Koshimizu N, Imokawa S, Yamada T, Shirai T, Kasamatsu N, Suda T. Inoue Y, et al. Among authors: inui n. Cancer Chemother Pharmacol. 2015 Jul;76(1):155-61. doi: 10.1007/s00280-015-2784-x. Epub 2015 May 24. Cancer Chemother Pharmacol. 2015. PMID: 26003540 Clinical Trial.
478 results